USCOM LIMITED (ASX:UCM) - Ann: Appendix 4C - quarterly, page-23 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by DreadedTaipan: ↑

I emailed the following query to Rob Phillips today.
The recent China CCP belligerence towards all its neighbours under its new president has raised concerns over the companies vulnerability to any actions by the CCP outside of your control. My question is have you been thinking about this and perhaps re-prioritising Europe and US sales so we are not so dependent on China?

His response is below.
Thanks for your support and enquiry.
I certainly have considered a supporting international strategy in case this geopolitical argey-bargey gets serious. From Uscom’s perspective, and using the World Bank Numbers, China represents the biggest growth opportunity as they plan to shift their health DGP spend from 5.15% to 12%, which is massive. From the US perspective they are planning a shift from 17.6 to 12%; a massive contraction. Average world spend is 9.9% and Australia spends about 9.2% and Europe about 10.13%.
From Uscom’s point of view we are strongly committed to global markets and have offices in Sydney, Singapore, Beijing, Budapest, London and LA.
China: Our single biggest defence is to work closely and compliantly in China with Chinese staff and investors. While this isn’t perfect it is smart….. We have worked very hard on China and created great success from this with ~70% of our revenue sourced from China and we have established our own wholly owned subsidiary in Beijing. We are definitely growing this part of our business and with our strong local Uscom China team have great opportunities and are receiving great local support at a Government, Hospital and vendor level. Additionally China is rapidly rebounding with manufacturing indexes already positive for the last two months with infection rates almost zero, while the US has had negative manufacturing indexes for the last 4 months and has rampant infections.
Europe: We already manufacture in Budapest and have just appointed a local salesperson to lead a small sales team and distribution network. The objective of which is to establish a network of sales people to sell our USCOM 1A. BP+ and SpiroSonic and VENTITEST devices throughout Europe. This is a low cost high efficiency operation which was ready to start in January – immediately prior to COVID again. We are slowly starting to activate this network as the single Eu countries start to emerge from the pandemic.
US: As part of risk mitigation I have undertaken a revision of our US distribution strategy and now have appointed dealers to cover nearly 80% of the US. This was about to go live when COVID hit. The initiative is intact but unable to be implemented in the current environment, but will be as soon as feasible. However the US political landscape and health care system are very unstable and not likely to recover foreseeably, but we are there and active and prepared to upregulate.
My Euro and US moves we initiated nearly 2 years ago with the initiation of the US trade wars, as a risk mitigation strategy. We are now waiting for the pandemic to recede so they can be more widely activated.
So I am working on risk mitigation, and even better this strategy should result in a strong platform for global growth for Uscom. I am also aware of events and careful to keep informed if things change.
Again thanks for your support. Not sure why record receipts, revenue, sales and profitability have sent the share-price down; no explaining a traders market. Good fundamentals and smart business practice should always win.
Kind Regards
Rob

My take is they are doing all that can be done in this political and pandemic environment to mitigate risks and that things will pickup once some semblance of normality takes hold.

Expand

Thanks for posting. It seems now we may have an early insight into tomorrow's webinar.

Agree whole heartedly that there is nothing bad in the 4C, just short termers wanting to make quick $ and taking profit / or preserving capital have made a temporary dent in the SP. There's not many businesses globally that can say they haven't been affected by this pandemic in some form.

Record financial figures continue - tick;
Professional and competent management - tick;
Vision and plan in place - tick;
China is moving along - tick;
Euro is slowing being activated - tick...
US is on hold for now.

Positive update from a medium to long term position.

GLTAH

No.	Vol.	Price($)
1	500000	1.4¢

No.

Vol.

Price($)

500000

1.4¢

Price($)	Vol.	No.
1.9¢	46000	1

Price($)

Vol.

No.

1.9¢

46000

No.	Vol.	Price($)
1	500000	0.014
1	132270	0.012
1	100000	0.010
1	150000	0.008
2	2000000	0.001

No.

Vol.

Price($)

500000

0.014

132270

0.012

100000

0.010

150000

0.008

2000000

0.001

Price($)	Vol.	No.
0.019	46000	1
0.020	63256	1
0.021	24866	1
0.022	6549	1
0.055	95083	2

Price($)

Vol.

No.

0.019

46000

0.020

63256

0.021

24866

0.022

6549

0.055

95083

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $4.759M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Appendix 4C - quarterly, page-23

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4C - quarterly, page-23

Top Stories

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News